Fang-Ju Lin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6343185/publications.pdf

Version: 2024-02-01

	471061	454577
1,020	17	30
citations	h-index	g-index
57	57	1926
37	37	1920
docs citations	times ranked	citing authors
	1,020 citations 57 docs citations	1,020 17 citations h-index 57 57

#	Article	IF	CITATIONS
1	Comparison of risk of acute kidney injury between patients receiving the combination of teicoplanin and piperacillin/tazobactam. Journal of the Formosan Medical Association, 2022, 121, 117-125.	0.8	2
2	The waist-to-body mass index ratio as an anthropometric predictor for cardiovascular outcome in subjects with established atherosclerotic cardiovascular disease. Scientific Reports, 2022, 12, 804.	1.6	4
3	Amantadine treatment and delayed onset of levodopaâ€induced dyskinesia in patients with early Parkinson's disease. European Journal of Neurology, 2022, 29, 1044-1055.	1.7	10
4	Management of metastatic renal cell carcinoma following prior vascular endothelial growth factor-targeted therapy. Journal of the Chinese Medical Association, 2022, Publish Ahead of Print, .	0.6	5
5	Postâ€Intracranial Hemorrhage Antithrombotic Therapy in Patients With Atrial Fibrillation. Journal of the American Heart Association, 2022, 11, e022849.	1.6	7
6	Continuity and Completeness of Electronic Health Record Data for Patients Treated With Oral Hypoglycemic Agents: Findings From Healthcare Delivery Systems in Taiwan. Frontiers in Pharmacology, 2022, 13, 845949.	1.6	2
7	Evaluation of the Negative Predictive Value of Methicillin-Resistant Staphylococcus aureus Nasal Swab Screening in the Medical Intensive Care Units and Its Effect on Antibiotic Duration. Infection and Drug Resistance, 2022, Volume 15, 1259-1266.	1.1	3
8	Building an active medical product safety surveillance system in Taiwan: Adaptation of the U.S. Sentinel System common data model structure to the National Health Insurance Research Database in Taiwan. Pharmacoepidemiology and Drug Safety, 2021, 30, 97-101.	0.9	11
9	Nephrotoxicity of teicoplanin-based combination therapy: focus on piperacillin/tazobactam and other anti-pseudomonal \hat{l}^2 -lactams. Journal of Antimicrobial Chemotherapy, 2021, 76, 499-506.	1.3	7
10	Association between prior use of anti-diabetic medication and breast cancer stage at diagnosis. Expert Opinion on Drug Safety, 2021, 20, 235-243.	1.0	1
11	Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation and valvular heart disease. Current Medical Research and Opinion, 2021, 37, 535-542.	0.9	8
12	The Association Between the Use of Cholinesterase Inhibitors and Cardiovascular Events Among Older Patients With Alzheimer Disease. Mayo Clinic Proceedings, 2021, 96, 350-362.	1.4	5
13	Survival, health care resource utilization and expenditures of first-line treatments for multiple myeloma patients ineligible for transplant in Taiwan. PLoS ONE, 2021, 16, e0252124.	1.1	0
14	Prenatal antidepressant use and the implication of hypertensive disorders during pregnancy. American Journal of Obstetrics and Gynecology, 2021, 225, 672.e1-672.e11.	0.7	3
15	Effect of <scp>ICDâ€9â€CM</scp> to <scp>ICDâ€10â€CM</scp> coding system transition on identification of common conditions: An interrupted time series analysis. Pharmacoepidemiology and Drug Safety, 2021, 30, 1653-1674.	0.9	12
16	Renoprotective effect of SGLT-2 inhibitors among type 2 diabetes patients with different baseline kidney function: a multi-center study. Cardiovascular Diabetology, 2021, 20, 203.	2.7	8
17	Association between the prolonged use of magnesium sulfate for tocolysis and fracture risk among infants. Medicine (United States), 2021, 100, e28310.	0.4	1
18	Comparative Safety and Effectiveness of Inhaled Corticosteroid and Long-Acting \hat{I}^2 2-Agonist Combinations in Patients With COPD. Chest, 2020, 157, 1117-1129.	0.4	20

#	Article	IF	Citations
19	Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes and Endocrinology, the, 2020, 8, 27-35.	5.5	215
20	Nationwide trends in incidence, healthcare utilization, and mortality in hospitalized heart failure patients in Taiwan. ESC Heart Failure, 2020, 7, 3653-3666.	1.4	10
21	Prognostic effect of high-density lipoprotein cholesterol level in patients with atherosclerotic cardiovascular disease under statin treatment. Scientific Reports, 2020, 10, 21835.	1.6	5
22	Clinical pharmacy service and international collaboration: Model and experience from a medical center in Taiwan. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 959.	0.5	3
23	Reimbursement Lag of New Drugs Under Taiwan's National Health Insurance System Compared With United Kingdom, Canada, Australia, Japan, and South Korea. Clinical and Translational Science, 2020, 13, 916-922.	1.5	5
24	Response. Chest, 2020, 157, 1684.	0.4	0
25	Cost-effectiveness of statin therapy for secondary prevention among patients with coronary artery disease and baseline LDL-C 70–100Âmg/dL in Taiwan. Journal of the Formosan Medical Association, 2020, 119, 907-916.	0.8	2
26	Clinical outcomes of basal insulin and oral antidiabetic agents as an add-on to dual therapy in patients with type 2 diabetes mellitus. Scientific Reports, 2020, 10, 5746.	1.6	4
27	Characteristics and Treatment Response of Newly Diagnosed Advanced-Stage and Relapsed/Refractory Hodgkin Lymphoma in Taiwan: A Nationwide Retrospective Study. Blood, 2020, 136, 30-30.	0.6	0
28	Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study. Mayo Clinic Proceedings, 2019, 94, 1147-1157.	1.4	34
29	Blood NfL. Neurology, 2019, 93, e1104-e1111.	1.5	144
30	Risk of Hypoglycemia and Concomitant Use of Repaglinide and Clopidogrel: A Populationâ€Based Nested Caseâ€Control Study. Clinical Pharmacology and Therapeutics, 2019, 106, 1346-1352.	2.3	8
31	A Web-Based Clinical System for Cohort Surveillance of Specific Clinical Effectiveness and Safety Outcomes: A Cohort Study of Non–Vitamin K Antagonist Oral Anticoagulants and Warfarin. JMIR Medical Informatics, 2019, 7, e13329.	1.3	1
32	Comparative Effectiveness and Safety of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome or Percutaneous Coronary Intervention. Acta Cardiologica Sinica, 2019, 35, 508-521.	0.1	9
33	Effect of Statin Intensity on the Risk of Epilepsy After Ischaemic Stroke: Real-World Evidence from Population-Based Health Claims. CNS Drugs, 2018, 32, 367-376.	2.7	14
34	Association between nonsteroidal antiâ€inflammatory drugs and atrial fibrillation among a middleâ€aged population: a nationwide populationâ€based cohort. British Journal of Clinical Pharmacology, 2018, 84, 1290-1300.	1.1	9
35	Statin use associated with lower risk of epilepsy after intracranial haemorrhage: A populationâ€based cohort study. British Journal of Clinical Pharmacology, 2018, 84, 1970-1979.	1.1	21
36	Valuation of the EQ-5D-5L in Taiwan. PLoS ONE, 2018, 13, e0209344.	1.1	38

#	Article	IF	CITATIONS
37	On-treatment lipid profiles to predict the cardiovascular outcomes in ASCVD patients comorbid with chronic kidney disease – The multi-center T-SPARCLE registry study. Journal of the Formosan Medical Association, 2018, 117, 814-824.	0.8	9
38	Quality-adjusted Outcomes Stratified by Response in Patients With Advanced Non–Small-cell Lung Cancer Receiving First-line nab-Paclitaxel/Carboplatin or Paclitaxel/Carboplatin. Clinical Lung Cancer, 2018, 19, 401-409.e4.	1.1	2
39	Patient Experience-based Value Sets. Medical Care, 2017, 55, 979-984.	1.1	10
40	The Association Between the Use of Zolpidem and the Risk of Alzheimer's Disease Among Older People. Journal of the American Geriatrics Society, 2017, 65, 2488-2495.	1.3	26
41	Residual Risk Factors to Predict Major Adverse Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with and without Diabetes Mellitus. Scientific Reports, 2017, 7, 9179.	1.6	37
42	Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria. Kidney and Blood Pressure Research, 2017, 42, 358-368.	0.9	35
43	Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? ‒ Data from a multicenter registry cohort study in Taiwan. PLoS ONE, 2017, 12, e0186861.	1.1	20
44	Positive Outcomes of Varicose Vein Surgery: The Patient Perspective. Patient, 2015, 8, 329-337.	1.1	3
45	HPLC-Fingerprints and Antioxidant Constituents of <i>Phyla nodiflora </i> . Scientific World Journal, The, 2014, 2014, 1-8.	0.8	22
46	Age-associated impact on presentation and outcome for penetrating thoracic trauma in the adult and pediatric patient populations. Journal of Trauma and Acute Care Surgery, 2014, 76, 273-278.	1.1	18
47	Evaluating change using patient-reported outcome measures in knee replacement: the complementary nature of the EQ-5D index and VAS scores. European Journal of Health Economics, 2014, 15, 489-496.	1.4	18
48	Measuring health-related quality of life in chronic obstructive pulmonary disease: properties of the EQ-5D-5L and PROMIS-43 short form. BMC Medical Research Methodology, 2014, 14, 78.	1.4	46
49	The incidence of acute venous injury as a result of proximity penetrating trauma screened with colour flow duplex ultrasound. Injury, 2014, 45, 192-196.	0.7	7
50	Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention. Pharmacy Practice, 2014, 12, 0-0.	0.8	21
51	Evaluation of content on EQ-5D as compared to disease-specific utility measures. Quality of Life Research, 2013, 22, 853-874.	1.5	26
52	Utilization of Cardiothoracic Surgeons for Operative Penetrating Thoracic Trauma and Its Impact on Clinical Outcomes. Annals of Thoracic Surgery, 2013, 96, 445-450.	0.7	14
53	Evaluation of changes in guidelines for medication management of stable chronic obstructive pulmonary disease. Journal of Evaluation in Clinical Practice, 2012, 19, n/a-n/a.	0.9	4
54	Chest Computed Tomography for Penetrating Thoracic Trauma After Normal Screening Chest Roentgenogram. Annals of Thoracic Surgery, 2012, 93, 1830-1835.	0.7	27

#	Article	lF	CITATIONS
55	Appropriateness of ambulatory prescriptions in Taiwan: translating claims data into initiatives. International Journal of Clinical Pharmacy, 2012, 34, 72-80.	1.0	6
56	Effects of clinical decision support on venous thromboembolism risk assessment, prophylaxis, and prevention at a university teaching hospital. American Journal of Health-System Pharmacy, 2010, 67, 1265-1273.	0.5	38